Overview

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Status:
Not yet recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

This is a Phase Ib/II study. The objectives are to evaluate the safety/tolerability and efficacy of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC, to characterize pharmacokinetics (PK) of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Zhejiang Genfleet Therapeutics Co., Ltd.

Treatments:

Cetuximab